More about IQVIA Holdings Inc.
Regulatory Filings for IQVIA Holdings Inc.
Fundamentals for IQVIA Holdings Inc.
Fraud, Delays, and High Fees—Gone: The Underrated Fintech Shift Reshaping U.S. Local Economies
From Rhode Island to Vermont: The Proficiency Gap That's Quietly Dividing New England's Workforce
Regional Airports Poised for Growth Amid Airline Shakeups
From Fuel Shock to Factory Revival: The Surprising Rise of Hyper-Local Supply Chains in the U.S.
Fundamentals for IQVIA Holdings Inc.
Business Operations:
Sector: HealthcareIndustry: Diagnostics & Research
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
Revenue projections:
IQV's revenue projections indicate a decrease from the prior year, which may make investors hesitant. A revenue decline could harm the company's bottom line, prompting investors to be more careful, as lower earnings often signal potential issues with profitability and future performance.
Financial Ratios:
| currentRatio | 0.749000 |
|---|---|
| forwardPE | 11.349116 |
| debtToEquity | 245.928000 |
| earningsGrowth | 0.236000 |
| revenueGrowth | 0.103000 |
| grossMargins | 0.332920 |
| operatingMargins | 0.151700 |
| trailingEps | 7.830000 |
| forwardEps | 14.079510 |
IQVIA Holdings Inc.'s Forward PE being in a good range indicates the stock is priced well relative to its earnings. It is not overvalued, leaving space for future growth, making it an appealing option for investors interested in long-term value appreciation.
IQV's high debt-to-equity ratio indicates significant leverage, meaning the company has more debt compared to its equity. While this can accelerate growth, it also increases financial risk if revenue or profits decline.
IQV's positive earnings and revenue growth suggest that the company is expected to expand its business. This reflects a healthy financial outlook, as IQV's increasing profits and sales signal further growth in the near future.
IQV's forward EPS surpassing its trailing EPS signals projected growth in profitability, with the company expected to perform better this year. This forecast suggests that IQV's earnings will improve compared to the previous financial year, highlighting optimism in its financial outlook.
Price projections:
Over time, IQV's price projections have steadily declined, reflecting reduced confidence in the company's future performance. The downward revisions suggest analysts are becoming more conservative in their assessments.
Insider Transactions:
In recent market activity, 3 sales of IQV shares took place, with market price at 211.5300038655599.The period under consideration did not see any sell transactions.The recent trend of more purchases than sales at IQV's current price could signal investor optimism. This pattern may point to a positive outlook for the stock, as it indicates growing confidence in its potential to perform well in the future.
Recommendation changes over time:
A recent buy bias from analysts toward IQV may inspire confidence in investors, who could view the stock as a promising investment. This positive sentiment suggests that IQV might be an appealing option for those looking to grow their wealth through stock market investments.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst technicals.
Latest Regulatory Filings for SP5
Companies with the best and the worst fundamentals.
AI Data Centers Transform Small-Town USA: Jobs, Taxes, and Tech Ecosystems Explode
The $919 Billion Warning: What the Wholesale Inventory Explosion Really Means for Main Street
How U.S. Cities Are Turning Data and Infrastructure into Billion-Dollar Opportunities